KGK Synergize Launches New Website at www.KGKSynergize.com
KGK Synergize Inc. (KGK) today, has announced the launch of a new website at www.kgksynergize.com to better service their contract research clientele.
London, Ont. -- April 7, 2005 - KGK Synergize Inc. (KGK) today, has announced the launch of a new website at www.kgksynergize.com to better service their contract research clientele. "The new look and navigational tools will be more user-friendly for those interested in learning how KGK can put solid research behind their products, in an effort to prove safety and efficacy," states Kristen Reynolds, Manager, Marketing & Sales. "More and more clients are looking to submit product health claims to the FDA and KGK can offer them the research services they need in order to do so."
The new website indicates the wide range of services that KGK can offer in-house from analytical testing, pre-clinical right through to human clinical trials.
"In addition, the new site will be regularly updated with new clinical recruitment opportunities as they arise for our clinical trial subject populations. This will give volunteers an easily accessible way to learn about what trial opportunities are offered through our clinic and how they can become involved," states Reynolds, "Coupled with our community press campaign, this will ease our recruitment process ensuring trials are filled in a timely manner."
KGK Synergize provides contract research services in the areas of nutraceutical research, analytical chemistry, immunology, toxicology, autoimmune diseases, etc. and clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
